Albany Molecular Research Company Profile (NASDAQ:AMRI)

Analyst Ratings

Consensus Ratings for Albany Molecular Research (NASDAQ:AMRI) (?)
Ratings Breakdown: 2 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $25.00 (74.46% upside)

Analysts' Ratings History for Albany Molecular Research (NASDAQ:AMRI)
Show:
DateFirmActionRatingPrice TargetActions
5/8/2016Morgan StanleyReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
10/26/2015First AnalysisUpgradeEqual Weight -> Overweight$25.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/6/2014JPMorgan Chase & Co.Reiterated RatingOverweight$25.00 -> $22.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/24/2014 forward)

Earnings

Earnings History for Albany Molecular Research (NASDAQ:AMRI)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/2/2016        
5/10/2016Q1$0.21$0.07$107.20 million$102.80 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/17/2016Q415$0.36$0.40$133.40 million$126.40 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/5/2015Q315$0.11$0.11$95.15 million$101.40 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/4/2015Q215$0.18$0.22$85.00 million$85.20 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/5/2015Q115$0.15$0.20$81.50 million$75.10 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/12/2015Q414$0.33$0.28$91.90 million$86.60 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/5/2014$0.16($0.02)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/5/2014Q214$0.20$0.22$65.64 million$68.20 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/6/2014Q114$0.23$0.16$62.19 million$51.00 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/12/2014Q4$0.17$0.22ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/6/2013Q313$0.11$0.13$62.10 million$53.00 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/6/2013Q2 2013$0.12$50.00 million$59.30 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/7/2013Q1 2013$0.10$0.23$53.70 million$59.40 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/12/2013Q4 2012$0.09$0.17$56.49 million$59.10 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/1/2012$0.02$0.01ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/9/2012$0.05$0.02ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/7/2012($0.12)($0.19)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/8/2011($0.05)($0.19)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/8/2011($0.03)($0.02)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/4/2011($0.14)($0.02)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/7/2011($0.15)($0.16)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Albany Molecular Research (NASDAQ:AMRI)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q2 20161$0.34$0.34$0.34
Q4 20161$0.40$0.40$0.40
Q1 20171$0.25$0.25$0.25
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Albany Molecular Research (NASDAQ:AMRI)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Albany Molecular Research (NASDAQ:AMRI)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
5/31/2016Kevin OconnorDirectorSell5,000$14.41$72,050.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/16/2016William S MarthCEOBuy12,500$12.86$160,750.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/13/2016George SvokosCOOBuy12,500$12.82$160,250.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/13/2016Steven R HagenSVPSell2,361$12.77$30,149.97View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/9/2015Ambra Constance M DMajor ShareholderSell50,000$19.60$980,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/17/2015Steven R HagenSVPSell1,000$20.45$20,450.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/10/2015Ambra Constance M DMajor ShareholderSell20,000$19.77$395,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/8/2015Steven R HagenSVPSell5,000$19.99$99,950.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/4/2015William S MarthCEOBuy10,000$19.98$199,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/1/2015Stuart M CableMajor ShareholderSell30,000$19.69$590,700.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/11/2015Ambra Constance M DMajor ShareholderSell20,000$19.11$382,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/8/2015Steven R HagenSVPSell14,500$19.27$279,415.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/10/2015Ambra Constance M DMajor ShareholderSell20,000$18.50$370,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/17/2015Steven R HagenSVPSell3,500$18.53$64,855.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/12/2015Kevin OconnorDirectorSell5,000$18.22$91,100.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/10/2015Ambra Thomas E Phd DDirectorSell20,000$17.65$353,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/10/2015George SvokosInsiderBuy10,000$17.72$177,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/5/2015William S MarthCEOBuy20,000$17.70$354,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/2/2015Stuart M CableMajor ShareholderSell30,000$16.39$491,700.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/10/2015Ambra Thomas E Phd DDirectorSell20,000$16.91$338,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/2/2015Stuart M CableMajor ShareholderSell30,000$16.32$489,600.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/12/2015Ambra Thomas E Phd DDirectorSell20,000$16.45$329,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/7/2015Stuart M CableMajor ShareholderSell7,694$16.00$123,104.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/5/2015Stuart M CableMajor ShareholderSell22,306$16.21$361,580.26View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/10/2014Ambra Constance M DMajor ShareholderSell20,000$16.24$324,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/5/2014Stuart M CableMajor ShareholderSell13,307$16.00$212,912.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/4/2014Stuart M CableMajor ShareholderSell16,693$16.00$267,088.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/10/2014William S MarthCEOBuy30,000$17.01$510,300.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/10/2014Ambra Constance M DMajor ShareholderSell20,000$21.62$432,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/1/2014Lori M HendersonSVPSell1,000$21.48$21,480.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/1/2014Stuart M CableMajor ShareholderSell30,000$21.61$648,300.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/10/2014Ambra Constance M DMajor ShareholderSell20,000$20.12$402,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/2/2014Lori M HendersonSVPSell2,500$19.56$48,900.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/28/2014Steven R HagenSVPSell1,250$19.74$24,675.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/14/2014Michael M NolanCFOSell10,000$19.76$197,600.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/12/2014Lori M HendersonSVPSell30,000$19.05$571,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/11/2014Ambra Thomas E Phd DDirectorSell20,000$18.99$379,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/8/2014Steven R HagenSVPSell10,797$18.99$205,035.03View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/1/2014Lori M HendersonSVPSell2,500$18.56$46,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/1/2014Stuart M CableMajor ShareholderSell30,000$18.69$560,700.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/10/2014Ambra Thomas E Phd DDirectorSell20,000$20.94$418,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/1/2014Lori M HendersonSVPSell2,500$20.62$51,550.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/1/2014Stuart M CableMajor ShareholderSell30,000$21.00$630,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/3/2014Steven R HagenSVPSell2,500$16.93$42,325.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/16/2014Steven HagenSVPSell1,250$15.45$19,312.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/15/2014George SvokosSVPBuy10,000$15.60$156,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/12/2014Steven HagenSVPSell5,897$15.00$88,455.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/12/2014William MarthCEOBuy30,000$15.40$462,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/1/2014Lori HendersonVPSell2,500$15.73$39,325.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/1/2014Stuart Cablemajor shareholderSell30,000$15.98$479,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/1/2014Lori HendersonVPSell2,500$18.74$46,850.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/1/2014Stuart Cablemajor shareholderSell30,000$18.52$555,600.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/27/2014Arthur RothDirectorSell5,000$15.95$79,750.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/27/2014Steven HagenSVPSell3,000$15.73$47,190.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/25/2014Steven HagenSVPSell2,500$15.19$37,975.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/24/2014Michael NolanCFOSell15,000$15.00$225,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/21/2014Steven HagenSVPSell1,500$14.87$22,305.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/19/2014Steven HagenSVPSell1,500$13.37$20,055.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/13/2014Stuart Cablemajor shareholderSell30,000$12.00$360,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/4/2013Steven HagenSVPSell2,500$10.93$27,325.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/3/2013William MarthDirectorBuy30,000$10.75$322,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/22/2013Steven HagenSVPSell2,300$11.55$26,565.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/22/2013William MarthDirectorBuy20,000$11.57$231,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/13/2013Stuart Cablemajor shareholderSell30,000$12.00$360,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/1/2013Stuart M CableMajor ShareholderSell30,000$12.53$375,900.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/1/2013Stuart M CableMajor ShareholderSell30,000$12.47$374,100.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/12/2013Stuart M CableMajor ShareholderSell30,000$12.00$360,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/22/2013Bruce J SargentSVPSell7,500$10.97$82,275.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/10/2013Steven R HagenSVPSell1,200$10.40$12,480.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/3/2012William S MarthDirectorBuy10,000$5.00$50,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/15/2012Ambra Thomas E Phd DCEOBuy10,000$3.80$38,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/9/2012Steven R HagenVPSell3,000$3.00$9,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Albany Molecular Research (NASDAQ:AMRI)
DateHeadline
07/18/16 02:31 PMAlbany Molecular Research, Inc. – Value Analysis (NASDAQ:AMRI) : July 18, 2016 -
07/15/16 01:05 PMAMRI to Announce Second Quarter 2016 Results
07/12/16 04:11 PMALBANY MOLECULAR RESEARCH INC Files SEC form 8-K, Completion of Acquisition or Disposition of Assets, Creation of a D -
07/11/16 07:32 AMAlbany Molecular Research, Inc. breached its 50 day moving average in a Bullish Manner : AMRI-US : July 11, 2016 -
07/11/16 06:43 AMAMRI Completes Acquisition of Euticals - [at noodls] - ALBANY, N.Y., July 11, 2016 /PRNewswire/ -- AMRI (NASDAQ: AMRI) today announced that it has completed the acquisition of Prime European Therapeuticals S.p.A., also known as 'Euticals', a privately-held ...
06/22/16 07:00 AMTeewinot Life Sciences Corporation Licenses Biosynthetic Technology to AMRI for the Production and Sale of the First Commercially Available CBCA Analytical Standard - [PR Newswire] - TAMPA, Fla. and ALBANY, N.Y., June 22, 2016 /PRNewswire/ -- Teewinot Life Sciences Corporation (Teewinot) and Albany Molecular Research, Inc. (AMRI) today announced that AMRI has licensed Teewinot's technology to produce and sell the first commercially available cannabichromene acid (CBCA) analytical standard. The CBCA analytical standard is manufactured using Teewinot's patented biosynthetic processes.
06/14/16 07:05 AMAMRI Selected as a Dedicated Chemical Biology Consortium Center to Expand Drug Development - [PR Newswire] - ALBANY, N.Y., June 14, 2016 /PRNewswire/ -- AMRI (AMRI) today announced that its Buffalo, N.Y. site has been selected to participate as a Dedicated Chemical Biology Consortium (CBC) Center for the Experimental Therapeutics (NExT) Program, centered at the Frederick National Laboratory for Cancer Research. The Frederick National Lab, sponsored by the National Cancer Institute, is managing the expansion of the Chemical Biology Consortium to 22 sites around the country with world-class expertise in high-throughput screening, structural biology, medicinal chemistry, compound profiling, cancer cell biology, and animal models for oncology.
06/13/16 07:17 AMAlbany Molecular Research, Inc. breached its 50 day moving average in a Bearish Manner : AMRI-US : June 13, 2016 -
06/09/16 08:24 PMDrug Discovery Informatics Market size is anticipated to reach around USD 6.5 billion by 2023
06/03/16 03:32 PMALBANY MOLECULAR RESEARCH INC Files SEC form 8-K, Change in Directors or Principal Officers, Submission of Matters to -
06/02/16 07:05 AMAlbany Molecular Research, Inc. breached its 50 day moving average in a Bullish Manner : AMRI-US : June 2, 2016 -
05/30/16 11:28 AMAlbany Molecular Research, Inc. (AMRI) Given Buy Rating at Morgan Stanley - Let Me Know About This - Albany Molecular Research, Inc. (AMRI) Given Buy Rating at Morgan StanleyLet Me Know About ThisAlbany Molecular Research logo Albany Molecular Research, Inc. (NASDAQ:AMRI)'s stock had its “buy” rating reissued by research analysts at Morgan Stanley in a research note issued on Sunday. In other news, CEO William S. Marth acquired 12,500 ...
05/29/16 10:39 AMAlbany Molecular Research, Inc. (NASDAQ:AMRI) Current Deferred Tax Assets At $3.586 Millions - RealistInvestor.com - Albany Molecular Research, Inc. (NASDAQ:AMRI) Current Deferred Tax Assets At $3.586 MillionsRealistInvestor.comAlbany Molecular Research, Inc. (NASDAQ:AMRI) accounts payable was $60.89 millions for the year closed 2013-12-31. For the quarter ended 2013-12-31 it was $60.89 millions. At the close of the fiscal 2013-12-31, the change in accounts payable was ...Is it Time to Cash in Profits on Albany Molecular Research Inc. (NASDAQ:AMRI)Franklin Independentall 2 news articles »
05/28/16 09:48 AMCommit To Purchase Albany Molecular Research At $10, Earn 18.6% Annualized Using Options - Investors considering a purchase of Albany Molecular Research Inc (Symbol: AMRI) shares, but tentative about paying the going market price of $14.25/share, might benefit from considering selling puts among the alternative strategies at their disposal.
05/27/16 10:54 AMTarget Check and Stock Performance Recap Albany Molecular Research, Inc. (NASDAQ:AMRI) - Wall Street Hints and News - Target Check and Stock Performance Recap Albany Molecular Research, Inc. (NASDAQ:AMRI)Wall Street Hints and NewsIn recent session activity, Albany Molecular Research, Inc. (NASDAQ:AMRI) shares have traded +1.095%. Monitoring the stock price relative to moving averages may provide enhanced perspective on share performance. After a recent check, the stock has ...and more »
05/24/16 12:36 PMAlbany Molecular Research, Inc. (NASDAQ:AMRI) Quarterly EPS From Continuing Operations Stands At $-0.29 - Investor Newswire - Albany Molecular Research, Inc. (NASDAQ:AMRI) Quarterly EPS From Continuing Operations Stands At $-0.29Investor NewswireAlbany Molecular Research, Inc. (NASDAQ:AMRI) diluted EPS from parent firm came at $-0.0694 for the year ended 2016-03-31. For the quarter ended 2016-03-31 it came at $-0.0694. Albany Molecular Research, Inc. (NASDAQ:AMRI) posted net basic EPS ...Albany Molecular Research (NASDAQ:AMRI) Shorted Shares Decreased By 8.87%Franklin IndependentAlbany Molecular Research, Inc. (NASDAQ:AMRI) Accounts Payable At $73.65Equities FocusAMRI CEO to Present at Jefferies 2016 Healthcare ConferencePR Newswire (press release)all 5 news articles »
05/23/16 07:16 AMAMRI CEO to Present at Jefferies 2016 Healthcare Conference - [at noodls] - ALBANY, N.Y., May 23, 2016 /PRNewswire/ -- Albany Molecular Research Inc. (NASDAQ: AMRI) announced today that William S. Marth, AMRI's President and Chief Executive Officer, will present at Jefferies 2016 ...
05/22/16 01:27 PMRevenue Update on Albany Molecular Research(NASDAQ:AMRI) - Trade Calls - Revenue Update on Albany Molecular Research(NASDAQ:AMRI)Trade CallsAlbany Molecular Research Inc. is a global contract research and manufacturing organization providing drug discovery development and manufacturing services. The Company operates in three business segments: Discovery and Development Services ...Is it Time to Cash in Profits on Albany Molecular Research Inc. (NASDAQ:AMRI)Franklin Independentall 2 news articles »
05/20/16 12:21 PMAnalyst Rating Check on Albany Molecular Research, Inc. (NASDAQ:AMRI) - Wall Street Hints and News - Analyst Rating Check on Albany Molecular Research, Inc. (NASDAQ:AMRI)Wall Street Hints and NewsThis research may involve tracking what professional equity analysts think about the company. Currently, sell-side analysts have provided a consensus stock rating of 1.17 on shares of Albany Molecular Research, Inc. (NASDAQ:AMRI). Analysts that cover ...and more »
05/20/16 12:21 PMALBANY MOLECULAR RESEARCH INC : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K) - Item 7.01 Regulation FD Disclosure. In connection with Albany Molecular Research, Inc.'s (the "Company") proposed purchase of 100% of the capital stock of Prime European Therapeuticals S.p.A. - Euticals ("Euticals"), a description of which was previously ...
05/20/16 05:03 AMALBANY MOLECULAR RESEARCH INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits -
05/19/16 05:57 PMETF’s with exposure to Albany Molecular Research, Inc. : May 19, 2016 -
05/19/16 12:04 PMALBANY MOLECULAR RESEARCH INC Financials -
05/18/16 12:41 PMAlbany Molecular Research Inc. (AMRI) is Trading Higher on Unusual Volume for May 16 - Equities.com - Albany Molecular Research Inc. (AMRI) is Trading Higher on Unusual Volume for May 16Equities.comAlbany Molecular Research Inc. (AMRI) experienced unusually high volume on May. 16, as the stock gained 1.59% to a closing price of $12.78. The stock saw 713,854 shares trade hands over the course of the day on 5,442 trades. Given that the stock's ...Keep an eye on Price Trends: Albany Molecular Research, Inc. (NASDAQ:AMRI) , The Medicines Company (NASDAQ ...Street UpdatesInsiders Accumulating Significant Shares: Albany Molecular Research, Inc. (NASDAQ:AMRI), Wendys Co (NASDAQ ...iStreetWireall 5 news articles »
05/17/16 11:13 AMAlbany Molecular Research, Inc. :AMRI-US: Earnings Analysis: Q1, 2016 By the Numbers -
05/14/16 06:17 AMConsensus Rating Review for Albany Molecular Research, Inc. (NASDAQ:AMRI) - Wall Street Hints and News - Consensus Rating Review for Albany Molecular Research, Inc. (NASDAQ:AMRI)Wall Street Hints and NewsOne of these bases is following what opinions professional research analysts have on a particular stock. Equity research analysts currently have a consensus rating of 1.17 on shares of Albany Molecular Research, Inc. (NASDAQ:AMRI). Sell-side analysts ...and more »
05/13/16 06:30 AMBroker Roundup For Albany Molecular Research, Inc. (NASDAQ:AMRI) - Share Trading News - Broker Roundup For Albany Molecular Research, Inc. (NASDAQ:AMRI)Share Trading News02/21/2014 – Albany Molecular Research, Inc. was upgraded to “buy” by analysts at McLean Capital Management. The share price of Albany Molecular Research, Inc. (NASDAQ:AMRI) was down -2.03% during the last trading session, with a day high of 13.66 ...Albany Molecular Research, Inc. (AMRI) Reaches New 52-Week LowFinance Dailyall 2 news articles »
05/13/16 06:30 AMPerformance Recap and Target Perspective on Albany Molecular Research, Inc. (NASDAQ:AMRI) - Wall Street Hints and News - Performance Recap and Target Perspective on Albany Molecular Research, Inc. (NASDAQ:AMRI)Wall Street Hints and NewsIn the latest trading session, shares of Albany Molecular Research, Inc. (NASDAQ:AMRI) moved -1.77%. In order to gain some further insight on stock performance, we can take a look at the stock price relative to some moving averages. After a recent ...and more »
05/13/16 06:30 AMStock EPSunder Review: Albany Molecular Research (NASDAQ:AMRI) - News Oracle - Stock EPSunder Review: Albany Molecular Research (NASDAQ:AMRI)News OracleEarnings Estimate & Revenue Estimate of Albany Molecular Research, Inc. (NASDAQ:AMRI) for the Current Quarter Jun 16: For the current Quarter,3.00 analysts have given an Average earnings estimate of $0.30 per share.According to the Analysts, the Low ...and more »
05/13/16 06:30 AMTwo Movers inside Traders Radar: Albany Molecular Research, Inc. (NASDAQ:AMRI) , West Pharmaceutical Services ... - Street Updates - Two Movers inside Traders Radar: Albany Molecular Research, Inc. (NASDAQ:AMRI) , West Pharmaceutical Services ...Street UpdatesOn 5/12/2016, Albany Molecular Research, Inc. (NASDAQ:AMRI) ended trading session lower at $12.79 with -1.77%. The company traded a volume of 1.2 million shares as comparison to average volume of 325.29 thousand shares. During the 52 –week ...
05/11/16 05:57 AMAMRI - Albany Molecular Research Inc.: AMRI Appoints Louis Yu, Ph.D., as Senior Vice President, Quality and ... - The Wall Street Transcript - AMRI - Albany Molecular Research Inc.: AMRI Appoints Louis Yu, Ph.D., as Senior Vice President, Quality and ...The Wall Street TranscriptALBANY, N.Y., May 9, 2016 /PRNewswire/ -- AMRI (NASDAQ: AMRI) today announced that it has hired Louis Yu, Ph.D., to fill the newly created position of senior vice president of quality and compliance. Dr. Yu will report to William S. Marth, AMRI's ...Albany Molecular Research, Inc. (NASDAQ:AMRI) Basic Consolidated EPS At $-0.0694Investor NewswireAlbany Molecular Research (NASDAQ:AMRI) Sellers Increased By 7.08% Their ShortsFranklin IndependentAlbany Molecular Research Inc (NASDAQ:AMRI): Institutional Investor Sentiment Up to 1.52B.O.D.Y Confidentialall 4 news articles »
05/11/16 05:57 AMAMRI - Albany Molecular Research Inc.: AMRI Clarifies 2016 Revenue Guidance - The Wall Street Transcript - AMRI - Albany Molecular Research Inc.: AMRI Clarifies 2016 Revenue GuidanceThe Wall Street TranscriptAlbany Molecular Research Inc. (AMRI) is a global contract research and manufacturing organization that has been working with the Life Sciences industry to improve patient outcomes and the quality of life for more than two decades. With locations in ...and more »
05/11/16 05:57 AMAMRI – Albany Molecular Research Inc.: AMRI Announces First Quarter 2016 Results - AMRI - Albany Molecular Research Inc. published this content on 10 May 2016 and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on 10 May 2016 11:43:10 UTC.
05/11/16 05:57 AMEast Syracuse company to move to Cicero, add 35 jobs - Cicero, N.Y. — An electrical contractor plans to move to Albany Molecular Research Inc.'s former drug research center in Cicero and create 35 new jobs at the larger facility. O'Connell Electric Co. said all 101 jobs at its offices on Stoutenger Street in ...
05/11/16 05:05 AMALBANY MOLECULAR RESEARCH INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements -
05/10/16 05:21 PMALBANY MOLECULAR RESEARCH INC Files SEC form 10-Q, Quarterly Report -
05/10/16 02:23 PMEdited Transcript of AMRI earnings conference call or presentation 10-May-16 12:30pm GMT -
05/10/16 09:28 AMAMRI Clarifies 2016 Revenue Guidance - [PR Newswire] - ALBANY, N.Y., May 10, 2016 /PRNewswire/ -- AMRI (NASDAQ: AMRI) clarified its 2016 revenue guidance, following the company's first quarter earnings conference call held earlier this morning. The company ...
05/10/16 07:30 AMAlbany Molecular Research Inc Earnings Call scheduled for 8:30 am ET today -
05/10/16 06:53 AMAlbany Molecular Research posts 1Q loss -
05/10/16 06:35 AMAMRI Announces First Quarter 2016 Results - [PR Newswire] - ALBANY, N.Y., May 10, 2016 /PRNewswire/ -- AMRI (NASDAQ: AMRI) today reported financial and operating results for the first quarter ended March 31, 2016 and provided an update to its outlook for 2016. ...
05/10/16 06:20 AMBuy Recommendations Count For Albany Molecular Research, Inc. (NASDAQ:AMRI) At 1 - RealistInvestor.com - Buy Recommendations Count For Albany Molecular Research, Inc. (NASDAQ:AMRI) At 1RealistInvestor.comZacks rating methodology assigns scores to companies on a simplified 1-5 scale. A score towards the 1-2 band indicates a Buy call, 3 score implies a Hold while a rating of 4 or 5 denotes Sell call. Each brokerage group has its own way of assigning ...and more »
05/10/16 06:20 AMMoody's affirms Albany Molecular's B3 CFR following announced acquisition of Euticals - Moodys.com (press release) (subscription) - Moody's affirms Albany Molecular's B3 CFR following announced acquisition of EuticalsMoodys.com (press release) (subscription)New York, May 09, 2016 -- Moody's Investors Service ("Moody's") today affirmed Albany Molecular Research Inc.'s (AMRI) ratings, including its B3 Corporate Family Rating (CFR), B3-PD Probability of Default Rating (PDR) and the B1 rating on the company's ...and more »
05/10/16 06:07 AMQ1 2016 Albany Molecular Research Inc Earnings Release - Before Market Open -
05/09/16 07:01 AMTrending Now: AMRI -
05/09/16 07:00 AMAMRI Appoints Louis Yu, Ph.D., as Senior Vice President, Quality and Compliance - [PR Newswire] - ALBANY, N.Y., May 9, 2016 /PRNewswire/ -- AMRI (NASDAQ: AMRI) today announced that it has hired Louis Yu, Ph.D., to fill the newly created position of senior vice president of quality and compliance. Dr. ...
05/06/16 04:33 PMALBANY MOLECULAR RESEARCH INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale of Eq -
05/06/16 06:27 AMAverage Analyst Rating for Albany Molecular Research, Inc. (NASDAQ:AMRI) - B.O.D.Y Confidential - Average Analyst Rating for Albany Molecular Research, Inc. (NASDAQ:AMRI)B.O.D.Y ConfidentialWall Street analysts have provided an average broker recommendation of 1.17 on Albany Molecular Research, Inc. (NASDAQ:AMRI) shares. The rating is determined by using the average of all analyst recommendations taken into consideration by Zacks ...and more »
05/06/16 06:27 AMAMRI to buy Euticals in $358mln deal to expand API business - Research and drug discovery firm Albany Molecular Research Inc (NASDAQ:AMRI) is set to buy Italy-based private firm Euticals for $358mln, in a deal which will open up new markets and is expected to be earnings enhancing in 2016. Founded over 30 years ago ...
03/14/16 07:00 AMAMRI Wins Four Life Science Leader Awards - [PR Newswire] - In 2013, AMRI was awarded a CMO Leadership Award in the Quality category. This year's awards will be presented at the CMO Leadership Awards Ceremony and Reception at the W Hotel on Wednesday, March 16, 2016 in New York City. "We are honored to be acknowledged once again as a CMO Leadership Award Winner," said William S. Marth, President and CEO, AMRI.

Social

About Albany Molecular Research

Albany Molecular Research logoAlbany Molecular Research, Inc. is a global contract research and manufacturing company. The Company provides drug discovery, development, and manufacturing services. The Company operates through three segments: Discovery and Development Services (DDS), Active Pharmaceutical Ingredients (API) and Drug Product Manufacturing (DPM). The DDS segment includes activities, such as drug lead discovery, optimization, drug development and small-scale commercial manufacturing. API includes pilot to commercial scale manufacturing of active pharmaceutical ingredients and intermediates and high potency and controlled substance manufacturing. DPM includes pre-formulation, formulation and process development through commercial scale production of complex liquid-filled and lyophilized injectable formulations. It supplies a range of services and technologies supporting the discovery and development of pharmaceutical products, the manufacturing of API and drug product for new and generic drugs.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: AMRI
  • CUSIP:
Key Metrics:
  • Previous Close: $14.47
  • 50 Day Moving Average: $14.09
  • 200 Day Moving Average: $14.98
  • P/E Ratio: N/A
  • P/E Growth: 1.46
  • Market Cap: $494.44M
  • Beta: 1.59
  • Current Year EPS Consensus Estimate: $1 EPS
  • Next Year EPS Consensus Estimate: $1.25 EPS
Additional Links:
Albany Molecular Research (NASDAQ:AMRI) Chart for Sunday, July, 24, 2016